33.94
Immunocore Holdings Plc Adr stock is traded at $33.94, with a volume of 202.35K.
It is down -3.50% in the last 24 hours and up +9.06% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$35.17
Open:
$35.04
24h Volume:
202.35K
Relative Volume:
0.55
Market Cap:
$1.70B
Revenue:
$345.60M
Net Income/Loss:
$-79.01M
P/E Ratio:
-21.15
EPS:
-1.6045
Net Cash Flow:
$-18.62M
1W Performance:
-8.10%
1M Performance:
+9.06%
6M Performance:
+5.80%
1Y Performance:
-15.42%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IMCR
Immunocore Holdings Plc Adr
|
33.94 | 1.77B | 345.60M | -79.01M | -18.62M | -1.6045 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-27-25 | Initiated | Deutsche Bank | Buy |
Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
Oct-24-24 | Initiated | UBS | Sell |
Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
Apr-29-24 | Initiated | Leerink Partners | Outperform |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-31-23 | Initiated | Robert W. Baird | Outperform |
Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-13-23 | Initiated | Needham | Buy |
Aug-16-23 | Initiated | CapitalOne | Overweight |
Jul-17-23 | Initiated | Canaccord Genuity | Hold |
Mar-31-23 | Initiated | Mizuho | Buy |
Mar-30-23 | Initiated | Guggenheim | Buy |
Mar-24-23 | Initiated | Bryan Garnier | Buy |
Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
Nov-30-22 | Initiated | Barclays | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
Aug-08-22 | Initiated | Cowen | Outperform |
Aug-02-22 | Initiated | BTIG Research | Buy |
Feb-08-22 | Initiated | H.C. Wainwright | Buy |
Oct-20-21 | Initiated | Oppenheimer | Outperform |
Mar-02-21 | Initiated | Goldman | Neutral |
Mar-02-21 | Initiated | JP Morgan | Overweight |
Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
Apellis Stock Rises On $300M Royalty Deal With Sobi For Aspaveli - Barchart.com
Oppenheimer Asset Management Inc. Makes New Investment in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Brokers Set Expectations for Immunocore FY2026 Earnings - Defense World
GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR) - Defense World
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
H.C. Wainwright reiterates buy rating on Immunocore stock amid ASCO update - Investing.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):